Quick answer: Sermorelin is generally ruled out for anyone with active or recent cancer, anyone pregnant or breastfeeding, and anyone with a pituitary tumor or a history of pituitary surgery or radiation. Uncontrolled diabetes, significant untreated illness, and certain other endocrine conditions may also exclude you or require clearance first. A licensed clinician makes that determination after reviewing your full history, medication list, and appropriate labs. Compounded sermorelin is not FDA-approved, and a prescription is not guaranteed.
Sermorelin exclusions exist because the pathway it acts on is a growth signaling pathway, not because providers are being cautious for the sake of it. Screening questions at intake are the point of the process rather than an obstacle in front of it. Answering them honestly, including the parts you would rather leave out, is what makes the decision a clinical one.
Active or recent cancer is a hard stop
Active cancer or a recent malignancy is treated as an absolute exclusion, and the reasoning is mechanistic. Sermorelin raises growth hormone signaling, which in turn raises IGF-1, and IGF-1 is a growth factor that promotes cell proliferation and reduces programmed cell death. Cancers are defined by uncontrolled proliferation, so raising a proliferative signal in someone with an active malignancy is a risk clinicians are not willing to take.
Much of that mechanistic picture comes from cell culture and animal research rather than from human trials of sermorelin, and direct human evidence on cancer risk with sermorelin specifically is limited. Limited human evidence is a reason for more caution rather than less, which is exactly why the field errs toward exclusion. A history of cancer that is years behind you is still a conversation for your clinician and your oncologist, not a form field to skip.
Pregnancy and breastfeeding
Pregnancy and breastfeeding rule out sermorelin. Safety data in pregnancy and lactation is absent rather than reassuring, and no clinician is going to expose a pregnancy to a growth signaling agent on the basis of missing information. Anyone who is pregnant, trying to conceive, or breastfeeding should be excluded from treatment.
Pituitary tumors and prior pituitary surgery or radiation
Pituitary conditions matter more here than for most medications, because the pituitary is the gland sermorelin acts on. Sermorelin is a growth hormone releasing hormone analog that prompts the pituitary to release its own growth hormone, so a pituitary tumor, a history of pituitary surgery, or prior radiation to that area changes the calculation entirely. A gland that has been operated on, irradiated, or displaced by a tumor does not behave predictably when stimulated.
Disclose any imaging of your head or pituitary, any diagnosis of a pituitary adenoma, and any prior endocrine surgery at intake. Related hormone disorders may also require endocrinology clearance before anything proceeds. Your clinician decides whether the history is disqualifying or simply requires more information.
Uncontrolled diabetes and other metabolic conditions
Uncontrolled diabetes is a common reason to defer or decline. Growth hormone signaling influences insulin sensitivity and glucose handling, so adding it on top of blood sugar that is already poorly controlled is not a sensible order of operations. Getting glucose control addressed first is the reasonable path, and your clinician may revisit the question afterward.
Significant untreated illness of other kinds, including thyroid disorders, unmanaged cardiovascular disease, and active infections, may also exclude you or require clearance. Your full medication list matters as well, since interactions and overlapping hormonal effects change the picture. Nothing here replaces the judgment of the clinician reviewing your case.
Why a provider may decline even when you look eligible on paper
Providers decline for reasons that have nothing to do with a checklist, and a good one will sometimes say no to someone who technically qualifies. Symptoms that bring men to sermorelin are frequently caused by something else, and treating the wrong thing is worse than treating nothing. Fragmented sleep, flat drive, and stalled recovery commonly reflect untreated sleep apnea, thyroid dysfunction, low testosterone, depression, or a side effect of a medication you are already taking.
Each of those deserves its own evaluation first, and several of them have well established treatments that sermorelin would only obscure. Men who are sleeping four hours a night, drinking heavily, or not training at all will usually be told to address those before anything is prescribed. Being declined is the system working rather than failing, and a provider who never declines anyone is telling you something about how they operate. Our guide to what a legitimate online evaluation looks like covers what to watch for.
Frequently Asked Questions
Who should not take sermorelin?
Sermorelin is generally not appropriate for anyone with active or recent cancer, anyone pregnant or breastfeeding, anyone with a pituitary tumor or prior pituitary surgery or radiation, and anyone with uncontrolled diabetes or significant untreated illness. Minors are excluded, and sermorelin is not appropriate for adults seeking athletic advantage. Final eligibility is determined by a licensed clinician, and a prescription is not guaranteed.
Can I take sermorelin if I had cancer years ago?
A remote cancer history is not automatically the same as active disease, but it is not a footnote either. Because sermorelin raises IGF-1, a growth factor that promotes cell proliferation, your clinician will want the details and may want input from your oncologist before deciding. Expect a more conservative answer here than you would get for most medications.
Does a family history of cancer disqualify me?
Family history is one input among several rather than an automatic exclusion, and how much weight it carries depends on which cancers, in which relatives, and at what ages. Disclose it fully and let the clinician weigh it. Withholding it to improve your odds of approval defeats the purpose of the screen.
What if my sleep problem is actually sleep apnea?
Sleep apnea is one of the most common explanations for the exact complaints that bring men to sermorelin, and it has effective, well established treatment. A clinician who suspects it should route you to evaluation rather than prescribing around it. Sorting that out first is more likely to change how you feel than anything else on the table, and our piece on what sermorelin timelines realistically look like assumes the underlying causes have already been addressed.
Do I have to disclose supplements and other peptides?
Disclose everything, including supplements, over the counter products, and anything bought from a research chemical site. Clinicians need the full picture to assess interactions and to know what is already influencing your labs. Omissions here create risk that lands on you rather than on the form.
Is sermorelin safe just because it is not a controlled substance?
Not being federally controlled says nothing about whether sermorelin is appropriate for you specifically. Sermorelin remains a prescription medication requiring clinician evaluation, and compounded sermorelin is not FDA-approved. The legal status question is covered separately in our explainer on the legal and regulatory standing of sermorelin.
The honest summary
Exclusion criteria for sermorelin are not fine print, and the mechanistic reasoning behind the big ones is straightforward once stated plainly. Raising growth hormone signaling raises IGF-1, IGF-1 promotes cell proliferation, and that combination is unacceptable in the presence of active malignancy. Pregnancy, breastfeeding, pituitary disease, and uncontrolled diabetes each carry their own reasoning, and none of them are negotiable through persistence.
Beyond the formal list sits clinical judgment, which is the part people underestimate. A clinician who tells you that your fragmented sleep looks more like apnea than like age is giving you the more useful answer, even though it is not the one you came for. Restoration starts with treating the right thing.
References
Primary sources for the claims above. Where a study is preclinical, that is stated in the section it supports.
Systematic review: the safety and efficacy of growth hormone in the healthy elderly. Annals of internal medicine. 2007. PMID 17227934.
Insulin-Like Growth Factor-1 (IGF-1) and Its Monitoring in Medical Diagnostic and in Sports. Biomolecules. 2021. PMID 33557137.
Growth Hormone and Aging. Endocrinology and metabolism clinics of North America. 2023. PMID 36948778.
Compounded medications are not FDA-approved and are not the same as, nor a substitute for, FDA-approved products. Prescription products require an evaluation by a licensed provider who determines whether a prescription is appropriate. A prescription is not guaranteed. Individual results vary. Everhuman does not provide medical advice; clinical care is delivered by Arora Health.